Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 16, 2018. The report details the vesting of Deferred Bonus Awards and Matching Awards granted in 2015 under the 2009 Deferred Annual Bonus Plan (DABP). The three-year performance period for these awards concluded on December 31, 2017, with vesting occurring on February 15, 2018.
Key Financial Metrics and Performance Measures
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it discloses specific performance metrics used to determine executive compensation vesting for the 2015 awards:
- Adjusted Free Cash Flow: Achieved £12.47 billion against a threshold of £11.48 billion (63% of maximum vesting).
- Total Shareholder Return (TSR): Ranked 5th out of 10 global pharmaceutical companies (44% of maximum vesting).
- R&D New Products: Achieved sales of £11.266 billion against a maximum vesting threshold of £7.912 billion (100% of maximum vesting).
- Overall Vesting Outcome: 31% of the total award vested, while 69% lapsed.
- Share Prices at Vesting: Ordinary Shares closed at £13.004; American Depositary Shares (ADS) closed at $37.31.
Material Changes and Transactions
The filing reports the release of shares to Persons Discharging Managerial Responsibilities (PDMRs) based on the performance outcomes above. No material changes to the company's financial position or operations are disclosed in this document. The transactions involved the release of Ordinary Shares and ADSs at a price of £0.00/$0.00 (compensation vesting) on February 15, 2018, on the London Stock Exchange and New York Stock Exchange.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on future outlook, or discussion of risks and contingencies. It is strictly a notification of share award vesting and transaction details for specific executives.
Important Facts for Investor Verification
- Executive Compensation Performance: Verify the 31% vesting rate against the disclosed performance metrics (Free Cash Flow, TSR, and R&D sales) to assess management incentive alignment.
- Share Issuance Volume: Confirm the total number of shares released to executives (e.g., 21,096 shares to CEO Emma Walmsley, 34,344 shares to outgoing R&D President Peter Vallance) for dilution analysis.
- Performance Thresholds: Note that while R&D sales exceeded the maximum target, TSR and Free Cash Flow fell short of maximum vesting levels, resulting in significant lapses (69%) of the 2015 awards.
- Scope Limitation: Acknowledge that this document does not contain GSK's full financial results for the period; investors must refer to the company's 20-F or earnings releases for comprehensive financial data.